CD34 and non-Hodgkin lymphoma: In this randomized, double-blind study involving 101 patients with NHL, the number of patients who achieved a target collection of >5×106 CD34+ cells/kg (62% vs. 20%) or >2×106 CD34+ cells/kg (88% versus 66%) and underwent autologous transplantation (88% versus 68%) was higher in the plerixafor arm when compared to those in the placebo arm.